Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Cancer Gene Ther ; 21(2): 68-73, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24434571

ABSTRACT

Adenovirus (Ad) i-leader protein is a small protein of unknown function. The C-terminus truncation of the i-leader protein increases Ad release from infected cells and cytotoxicity. In the current study, we use the i-leader truncation to enhance the potency of an oncolytic Ad. In vitro, an i-leader truncated oncolytic Ad is released faster to the supernatant of infected cells, generates larger plaques, and is more cytotoxic in both human and Syrian hamster cell lines. In mice bearing human tumor xenografts, the i-leader truncation enhances oncolytic efficacy. However, in a Syrian hamster pancreatic tumor model, which is immunocompetent and less permissive to human Ad, antitumor efficacy is only observed when the i-leader truncated oncolytic Ad, but not the non-truncated version, is combined with gemcitabine. This synergistic effect observed in the Syrian hamster model was not seen in vitro or in immunodeficient mice bearing the same pancreatic hamster tumors, suggesting a role of the immune system in this synergism. These results highlight the interest of the i-leader C-terminus truncation because it enhances the antitumor potency of an oncolytic Ad and provides synergistic effects with gemcitabine in the presence of an immune competent system.


Subject(s)
Adenoviridae/genetics , Adenoviridae/physiology , Deoxycytidine/analogs & derivatives , Neoplasms/genetics , Oncolytic Virotherapy/methods , Protein Sorting Signals/genetics , Virus Release/physiology , Adenoviridae/pathogenicity , Animals , Cell Line, Tumor , Cricetinae , DNA Primers/genetics , Deoxycytidine/pharmacology , Fluorescence , HEK293 Cells , Humans , Immunohistochemistry , Mesocricetus , Mice , Mutation, Missense , Neoplasms/drug therapy , Statistics, Nonparametric , Virus Release/drug effects , Gemcitabine
2.
Gene Ther ; 19(11): 1048-57, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22113313

ABSTRACT

The limitations of the current oncolytic adenoviruses for cancer therapy include insufficient potency and poor distribution of the virus throughout the tumor mass. To address these problems, we generated an oncolytic adenovirus expressing the hyperfusogenic form of the gibbon-ape leukemia virus (GALV) envelope glycoprotein under the control of the adenovirus major late promoter. The oncolytic properties of the new fusogenic adenovirus, ICOVIR16, were analyzed both in vitro and in vivo, and compared with that of its non-fusogenic counterpart, ICOVIR15. Our results indicate that GALV expression by ICOVIR16 induced extensive syncytia formation and enhanced tumor cell killing in a variety of tumor cell types. When injected intratumorally or intravenously into mice with large pre-established melanoma or pancreatic tumors, ICOVIR16 rapidly reduced tumor burden, and in some cases, resulted in complete eradication of the tumors. Importantly, GALV expression induced tumor cell fusion in vivo and enhanced the spreading of the virus throughout the tumor. Taken together, these results indicate that GALV expression can improve the antitumoral potency of an oncolytic adenovirus and suggest that ICOVIR16 is a promising candidate for clinical evaluation in patients with cancer.


Subject(s)
Adenoviridae/genetics , Genetic Vectors , Giant Cells , Leukemia Virus, Gibbon Ape/genetics , Oncolytic Viruses , Adenoviridae/metabolism , Animals , Cell Line, Tumor , Cricetinae , Female , Gene Expression Regulation, Viral , Gene Order , Genetic Therapy , Genetic Vectors/administration & dosage , Genetic Vectors/adverse effects , Genetic Vectors/metabolism , Giant Cells/virology , Humans , Injections , Male , Mice , Neoplasms/genetics , Neoplasms/pathology , Neoplasms/therapy , Tumor Burden , Xenograft Model Antitumor Assays
3.
Gene Ther ; 19(4): 453-7, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21776023

ABSTRACT

Retargeting oncolytic adenoviruses from their systemic preeminent liver tropism to disseminated tumor foci would highly improve the efficacy of these agents at eradicating tumors. We have replaced the KKTK fiber shaft heparan sulfate glycosaminoglycan-binding domain with an RGDK motif in order to achieve simultaneously liver detargeting and tumor targeting. When inserted into a wild-type backbone, this mutation palliated liver transaminase elevation and hematological alterations in mice. Importantly, when tested in a backbone that redirects E1A transcription towards pRB pathway deregulation, RGD at this novel shaft location also improved significantly systemic antitumor therapy compared with the broadly used RGD location at the HI-loop of the fiber knob domain.


Subject(s)
Adenoviridae/genetics , Neoplasms/therapy , Oligopeptides , Oncolytic Virotherapy/methods , Animals , Binding Sites , Cell Line, Tumor , Gene Transfer Techniques , Genetic Vectors , Heparitin Sulfate/metabolism , Mice , Mice, Inbred BALB C , Receptors, Cell Surface/metabolism
4.
Cancer Gene Ther ; 17(11): 792-802, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20671769

ABSTRACT

Osteosarcoma (OSA) is the most common bone tumor affecting the dog. The veterinary options for therapeutic management of OSA are limited and prognosis for such patients is poor. Oncolytic adenoviruses are attractive tools for experimental therapeutics as they can replicate and spread within tumors to directly induce tumor destruction. However, a major impediment to systemic oncolytic adenoviruses injection is the presence of pre-existing neutralizing antibodies (Nabs). In this study, we investigated the effect of a replication-selective canine adenovirus (OCCAV) to treat OSA in the presence of Nabs and the use of canine OSA cells as carrier vehicles for evading Nabs. Our systemic biodistribution data indicated that canine tumor cells could successfully reach the tumor site and deliver OCCAV to tumor cells in an immunized mice model. Furthermore, the use of carrier cells also reduced adenovirus uptake by the liver. Importantly, OCCAV alone was not effective to control tumor growth in a pre-immunized xenograft mouse model. On the contrary, systemic antitumoral activity of carrier-cell OCCAV was evident even in the presence of circulating antibodies, which is a relevant result from a clinical point of view. These findings are of direct translational relevance for the future design of canine clinical trials.


Subject(s)
Adenoviruses, Canine/metabolism , Antibodies, Neutralizing/metabolism , Bone Neoplasms/metabolism , Oncolytic Viruses/genetics , Osteosarcoma/genetics , Adenoviruses, Canine/genetics , Adenoviruses, Canine/physiology , Animals , Antineoplastic Agents/metabolism , Cell Line, Tumor , Dogs , Genetic Vectors/metabolism , Humans , Immunization , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Oncolytic Viruses/metabolism , Virus Replication , Xenograft Model Antitumor Assays
5.
Cancer Gene Ther ; 17(7): 476-83, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20168350

ABSTRACT

Treatment of metastatic tumors with engineered adenoviruses that replicate selectively in tumor cells is a new therapeutic approach in cancer. Systemic administration of these oncolytic adenoviruses lack metastatic targeting ability. The tumor stroma engrafting property of intravenously injected mesenchymal stem cells (MSCs) may allow the use of MSCs as cellular vehicles for targeted delivery. In this work, we study the safety and the efficacy of infusing autologous MSCs infected with ICOVIR-5, a new oncolytic adenovirus, for treating metastatic neuroblastoma. Four children with metastatic neuroblastoma refractory to front-line therapies received several doses of autologous MSCs carrying ICOVIR-5, under an approved preliminary study. The tolerance to the treatment was excellent. A complete clinical response was documented in one case, and the child is in complete remission 3 years after this therapy. We postulate that MSCs can deliver oncolytic adenoviruses to metastatic tumors with very low systemic toxicity and with beneficial antitumor effects.


Subject(s)
Mesenchymal Stem Cells/virology , Neuroblastoma/therapy , Oncolytic Virotherapy/methods , Cell Line, Tumor , Child, Preschool , Humans , Male , Neuroblastoma/pathology , Neuroblastoma/virology , Oncolytic Viruses/physiology
6.
Methods Find Exp Clin Pharmacol ; 32 Suppl A: 3-7, 2010 Dec.
Article in Spanish | MEDLINE | ID: mdl-21381281

ABSTRACT

Oncolytic viruses represent a new treatment modality that may help overcome some of the most important limitations of classical radio- and chemotherapy. This new technique is based on conditioned replication of the viral genome only in cells with the genetic alterations characteristic of tumor lesions. This facilitates the selective lysis of tumor masses concomitant to viral autoamplification. As a result, the pharmacodynamic parameters involved are completely different from those of antitumor drug substances. ICOVIR-5 is an oncolytic adenovirus with a good toxicity and antitumor efficacy profile following intravenous administration. However, prior clinical experience has also revealed its most important limitations for ensuring clinical efficacy. The identification of these limitations, together with the possibilities for manipulating viral genomes, now open to door to the molecular designing of candidates offering more efficient antitumor activity and constituting genuine management alternatives in application to treatment-refractory tumors.


Subject(s)
Adenoviridae/genetics , Neoplasms/therapy , Oncolytic Virotherapy , Oncolytic Viruses/genetics , Virus Replication/genetics , Animals , Genetic Therapy/adverse effects , Humans , Neoplasms/virology , Oncolytic Virotherapy/adverse effects
7.
Gene Ther ; 16(12): 1441-51, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19710704

ABSTRACT

The E2F-1 promoter has been used to confer tumor-selective E1A expression in oncolytic adenoviruses. Tumor specificity is mainly conferred by a unique structure of E2F-responsive sites organized in palindromes. Binding of the E2F-pRb complex to these palindromes results in repression of transcription in normal cells. Owing to deregulation of the Rb/p16 pathway in tumor cells, binding of free E2F activates transcription and initiates an autoactivation loop involving E1A and E4-6/7. ICOVIR-7 is a new oncolytic adenovirus designed to increase the E2F dependency of E1A gene expression. It incorporates additional palindromes of E2F-responsive sites in an insulated E2F-1 promoter controlling E1A-Delta24. The E2F palindromes inhibited replication in normal cells, resulting in a low systemic toxicity at high doses in immunocompetent mice. The Delta24 deletion avoids a loop of E2F-mediated self-activation in nontumor cells. Importantly, the additional E2F-binding hairpins boost the positive feedback loop on the basis of E1A-mediated transcriptional regulation of E4-6/7 turned on in cancer cells and increased antitumoral potency as shown in murine subcutaneous xenograft models treated by intravenous injection. These results suggest that the unique genetic combination featured in ICOVIR-7 may be promising for treating disseminated neoplasias.


Subject(s)
Adenoviridae/genetics , Adenovirus E1A Proteins/biosynthesis , E2F1 Transcription Factor/genetics , Oncolytic Viruses/genetics , Promoter Regions, Genetic , Animals , Cell Line , Cell Line, Tumor , Gene Expression Regulation, Viral , Humans , Male , Mice , Mice, Nude , Oncolytic Virotherapy/methods , Virus Replication
8.
Gene Ther ; 15(17): 1240-5, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18509378

ABSTRACT

Fusogenic membrane glycoproteins (FMGs) may enhance the cytotoxicity of conditionally replicative adenoviruses. However, expression at early stages of infection impairs virus replication. We have inserted the hyperfusogenic form of the gibbon ape leukemia virus (GALV) envelope glycoprotein as a new splice unit of the major late promoter (MLP) to generate a replication-competent adenovirus expressing this protein. At high multiplicity of infection (MOI), this virus replicated efficiently forming clumps of fused cells and showing a faster release. In contrast, at low MOI, infected cells formed syncytia where only one nucleus contained virus DNA, decreasing total virus production but increasing cytotoxicity.


Subject(s)
Genetic Therapy/methods , Genetic Vectors/genetics , Giant Cells/physiology , Leukemia Virus, Gibbon Ape/physiology , Oncolytic Virotherapy/methods , Viral Fusion Proteins/genetics , Cell Line, Tumor , Gene Expression , Genetic Engineering , Humans , Leukemia Virus, Gibbon Ape/genetics , Promoter Regions, Genetic , Transgenes , Virus Replication
9.
Cancer Gene Ther ; 13(7): 696-705, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16498429

ABSTRACT

We previously described Ad-Delta24RGD as an enhanced-infectivity oncolytic adenovirus that targets tumors with an impaired RB pathway. The common alteration of this pathway in cancer eliminates the interaction of pRB with E2F and releases free E2F to activate E2F-responsive promoters, including the E2F-1 promoter. To improve the selectivity towards RB pathway-defective tumors and reduce the toxicity of Ad-Delta24RGD we aimed to control E1A-Delta24 expression under the E2F-1 promoter. A polyA signal was inserted upstream of the E2F-1 promoter to stop transcription initiated at the adenovirus ITR and packaging signal. The human myotonic dystropy locus insulator (DM-1) was also located between the E1a enhancers and the E2F-1 promoter to further insulate the promoter. The Ad-Delta24RGD derivative containing these insulation sequences expressed less E1a-Delta24 in normal cells and resulted less toxic while maintaining the potent oncolytic activity of the parental virus. These results demonstrate that the human DM-1 inslulator can function in an adenovirus context to maintain heterologous promoter selectivity. The new oncolytic adenovirus presented here may represent a valuable therapeutic option for a broad range of tumors with a deregulated E2F/pRB pathway.


Subject(s)
Adenoviridae/genetics , Adenovirus E1A Proteins/genetics , E2F1 Transcription Factor/genetics , Gene Expression Regulation, Viral/genetics , Promoter Regions, Genetic/genetics , Cell Line, Transformed , Cell Line, Tumor , Codon, Terminator/genetics , Genetic Therapy , Humans , Neoplasms/genetics , Neoplasms/therapy , Polyadenylation/genetics
10.
Oncology ; 67(3-4): 277-90, 2004.
Article in English | MEDLINE | ID: mdl-15557790

ABSTRACT

We analyzed the differential gene expression in the pancreatic cancer cell line NP-18 upon induction of apoptosis caused by cyclin-dependent kinase inhibition triggered by either overexpression of the tumor suppressor gene p16(INK4A)using an adenoviral construction or incubation with the chemical inhibitors, roscovitine or olomoucine. Screening was performed using cDNA arrays from Clontech that allowed the determination of the expression of 1,176 genes specifically related with cancer. The analysis was carried out using the Atlas Image 2.01 (Clontech) and GeneSpring 4.2 (Silicon Genetics) softwares. Among the differentially expressed genes, we chose for further validation histone deacetylase 1 (HDAC1), von Hippel Lindau and decorin as upregulated genes, and Sp1, hypoxia-inducible factor-1 alpha and DNA primase as downregulated genes. The changes in the expression of these genes to mRNA were validated by quantitative RT-PCR and the final translation into protein by Western blot analysis. Inhibition of HDAC activity, Sp1 binding and DNA primase expression led to an increase in the level of apoptosis, both in parental cells and in doxorubicin-resistant cells. Therefore, these proteins could constitute possible targets to develop modulators in cancer chemotherapy that would increase or restore apoptosis.


Subject(s)
Apoptosis , Biomarkers, Tumor/analysis , Cyclin-Dependent Kinase Inhibitor p16/genetics , Gene Expression Profiling , Genes, p16 , Pancreatic Neoplasms/chemistry , Protein Kinase Inhibitors/pharmacology , Adenoviridae , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Blotting, Western , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p16/analysis , DNA Primase/analysis , DNA-Binding Proteins/analysis , Decorin , Down-Regulation , Extracellular Matrix Proteins , Gene Expression Regulation, Neoplastic/drug effects , Genes, p16/drug effects , Genetic Vectors , Histone Deacetylase 1 , Histone Deacetylases/analysis , Humans , Hypoxia-Inducible Factor 1 , Hypoxia-Inducible Factor 1, alpha Subunit , Kinetin , Nuclear Proteins/analysis , Pancreatic Neoplasms/drug therapy , Proteoglycans/analysis , Purines/pharmacology , Reverse Transcriptase Polymerase Chain Reaction , Roscovitine , Transcription Factors/analysis , Tumor Suppressor Proteins/analysis , Ubiquitin-Protein Ligases/analysis , Up-Regulation , Von Hippel-Lindau Tumor Suppressor Protein
11.
Cancer Gene Ther ; 8(10): 740-50, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11687897

ABSTRACT

Pancreatic cancer has long carried poor prognosis. The development of new therapeutic approaches is particularly urgent. Inactivation of the tumor-suppressor gene p16(INK4a/CDKN2), a specific inhibitor of the cyclin-dependent kinases CDK4 and CDK6, is the most common genetic alteration in human pancreatic cancer, making it an ideal target for gene replacement. Here we transfected tumor cells using a recombinant adenovirus containing the wt-p16 cDNA (Ad5RSV-p16). The overexpression of p16 decreased cell proliferation in all four human pancreatic tumor cell lines (NP-9, NP-18, NP-29, and NP-31). However, G1 arrest and senescence were observed in only three. In contrast, the fourth (NP-18) showed a significant increase in apoptosis. This differential behavior may be related to the differences found in the expression level of E2F-1. Experiments on subcutaneous pancreatic xenografts demonstrated the effectiveness of p16 in the inhibition of pancreatic tumor growth in vivo. Taken together, our results indicate that approaches involving p16 replacement are promising in pancreatic cancer treatment.


Subject(s)
Adenocarcinoma/therapy , Adenoviridae/genetics , Apoptosis , Cyclin-Dependent Kinase Inhibitor p16/genetics , Genetic Therapy/methods , Pancreatic Neoplasms/therapy , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Animals , Blotting, Western , Bromodeoxyuridine , Cell Cycle/genetics , Cellular Senescence , Genetic Vectors , Humans , Mice , Mice, Inbred BALB C , Mice, Nude , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Transfection , Tumor Cells, Cultured , beta-Galactosidase/metabolism
12.
Ann Oncol ; 12(3): 379-88, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11332152

ABSTRACT

BACKGROUND: Strategies based on the introduction of pro-drug activating enzymes or the restoration of tumour suppressor genes have been proposed as encouraging methods to improve the efficiency of treatments in pancreatic cancer. The in situ bioactivation of cyclophosphamide by cytochrome p450-2B1 and subsequent p53 delivery were examined. MATERIALS AND METHODS: NP-18 cell line derived from a human pancreatic adenocarcinoma was treated in vitro with a combination of the Adenovirus-CYP2B1/cyclophosphamide and adenoviral-mediated wt-p53 reintroduction. Cell viability and cytometric cell cycle profiles were analyzed to evaluate the sensitivity of NP-18 cells to this treatment. The efficiency of this combination was assessed in an in vivo model consisting of xenografts into the subcutaneous tissue of Balb/c mice by tumour growth, histological analysis and cell cycle determinations. RESULTS: Ad-CYP2B1/cyclophosphamide or Ad-p53 treatments led to a marked decrease in cell viability of NP-18 cells. Combination of both treatments elicited a higher loss of cell viability and marked increases in sub-G1 population in cell cycle profiles. Animals treated with the combination strategy showed a quick reduction of tumour volumes due to the bioactivation of cyclophosphamide by CYP2B1 and sustained growth inhibition throughout the period evaluated after p53 delivery. Only this group of animals presented statistically significant differences with respect to control and cyclophosphamide-treated groups (P < 0.05). CONCLUSIONS: These results indicate that in situ bioactivation of cyclophosphamide by CYP2B1 and the recognition of the damaged DNA by p53 increase tumour regressions and may be a promising therapy for solid tumour therapy in man.


Subject(s)
Adenocarcinoma/therapy , Adenoviridae/genetics , Antimetabolites, Antineoplastic/therapeutic use , Cyclophosphamide/therapeutic use , Cytochrome P-450 CYP2B1/genetics , Genes, p53/genetics , Pancreatic Neoplasms/therapy , Adenocarcinoma/enzymology , Animals , Biotransformation , Blotting, Western , Cytochrome P-450 CYP2B1/metabolism , Gene Transfer Techniques , Genetic Vectors , Humans , Mice , Mice, Inbred BALB C , Mice, Nude , Pancreatic Neoplasms/enzymology , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/enzymology , Tumor Suppressor Protein p53/metabolism
13.
Cancer Gene Ther ; 7(4): 545-56, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10811472

ABSTRACT

Chemotherapy does not significantly improve prognosis in pancreatic cancer. New therapeutical approaches involving p53 gene replacement appear to be very encouraging due to the key role of p53 in the cell response to DNA damage. Here, we have evaluated the effectiveness of combining wild-type p53 (wt-p53) gene reintroduction (Ad5CMV-p53) and exposure to two genotoxic drugs, gemcitabine and cisplatin, in several human pancreatic cell lines. The efficiency of the combinations was clearly dependent upon timing, as assessed by cell survival determinations. Although wt-p53 transduction before drug treatment induced chemoresistance, p53 transduction in cells treated previously with gemcitabine increased cytotoxicity. Cell cycle profiles showed significant decreases in the percentage of cells in the S phase as a consequence of arrests provoked by the expression of exogenous p53, reducing the number of cells susceptible to the drug. The sensitivity of cells to cisplatin, which has a lower degree of S-phase specificity, was not modified as much by p53 gene replacement. In contrast, the recognition of the previous drug-induced DNA damage by the newly expressed wt-p53 elicited increases in sub-G1 populations, consistent with the annexin determinations and bax/bcl-2 ratios observed. Experiments on subcutaneous pancreatic xenografts corroborated the effectiveness of this approach in vivo. Thus, the combination of p53 transduction and chemotherapy, under a correct schedule of administration, appears to be a very promising therapy for human pancreatic cancer.


Subject(s)
Adenoviridae/genetics , Antimetabolites, Antineoplastic/toxicity , Cell Survival/drug effects , Cisplatin/toxicity , Deoxycytidine/analogs & derivatives , Genes, p53 , Apoptosis/drug effects , Cell Cycle/drug effects , DNA Damage , Deoxycytidine/toxicity , Dose-Response Relationship, Drug , Genetic Vectors , Humans , Recombinant Fusion Proteins/biosynthesis , Transfection , Tumor Cells, Cultured , beta-Galactosidase/analysis , beta-Galactosidase/genetics , Gemcitabine
14.
Cancer Gene Ther ; 6(5): 428-36, 1999.
Article in English | MEDLINE | ID: mdl-10505853

ABSTRACT

The development of new therapies is particularly urgent with regard to pancreatic tumors. Gene therapy approaches involving p53 replacement are promising due to the central role of p53 in the cellular response to DNA damage and the high incidence of p53 mutations in pancreatic tumors. Adenoviruses containing wild-type (wt) p53 cDNA (Ad5CMV-p53) were introduced into four human pancreatic cell lines to examine the impact caused by exogenous wt p53 on these cells. Introduction of wt p53 in mutant p53 cells (NP-9, NP-18, and NP-31) caused marked falls in cell proliferation and rises in the level of apoptosis. In contrast, overexpression of p53 did not induce apoptosis in NP-29 (wt p53). The presence of p16 contributes to the induction of apoptosis, as demonstrated by introduction of the wt p16 gene (Ad5RSV-p16). Analysis of cell cycle and apoptosis in etoposide-treated cells corroborated the inability of NP-29 to die by apoptosis, suggesting that this wt p53 cell line lacks p53 downstream functions in the apoptosis pathway. Taken together, our results indicate that the effects elicited by exogenous p53 protein depend upon the molecular alterations related to p53 actions on cell cycle and apoptosis. Therefore, knowledge of the genetic background of tumor cells is crucial to the development of efficient therapies based on the introduction of tumor suppressor genes.


Subject(s)
Adenocarcinoma/genetics , Adenoviridae/genetics , Pancreatic Neoplasms/genetics , Tumor Suppressor Protein p53/genetics , Adenocarcinoma/pathology , Animals , Apoptosis/drug effects , Apoptosis/genetics , Cell Cycle/drug effects , Cell Cycle/genetics , Etoposide/pharmacology , Genetic Vectors , Humans , Mice , Mice, Nude , Pancreatic Neoplasms/pathology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...